Seoul: Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, announced it has entered into a partnership with a U.S. company to distribute its ophthalmology biosimilars in the United States.

According to Yonhap News Agency, the company has finalized a commercialization agreement with Harrow Inc., a prominent U.S. eye care pharmaceutical firm. This agreement will enable Harrow to sell Byooviz and Opuviz through its extensive sales network. Byooviz and Opuviz are biosimilars of the original drugs Lucentis and Eylea, respectively.

The agreement's activation is contingent upon the completion of the transfer of commercial rights from the U.S. biotechnology firm Biogen Inc. to Samsung Bioepis by the end of 2025. Samsung Bioepis expressed its intent to collaborate closely with Harrow, which possesses significant expertise in marketing ophthalmic pharmaceutical products within the North American market.